Just released data at the American Urological Association annual meeting in Chicago from a long-term study of Provenge, an anti-cancer vaccine in men with advanced prostate cancer shows a significant survival advantage for men who take the drug. Researchers say they are encouraged by the findings, citing an impressive effect on long-term survival for patients, compared to placebo. Experts say these results also validate the long-term hope in new drugs to harness a patient's own immune system to fight cancer. This Live 30-minute Patient Power webcast allows men living with advanced prostate cancer to ask questions about the study results directly of two leading experts.
|
|
Christopher Amling, M.D., F.A.C.S.
Head of the Division of Urology in the Department of Surgery, Oregon Health & Science University
Dr. Christopher Amling is head of the Division of Urology in the Department of Surgery, OHSU School of Medicine, OHSU Knight Cancer Institute. Dr. Amling is an expert in advanced minimally invasive management of urologic diseases, including robotic surgery for prostate and bladder cancer, and prostate cancer and outcomes research. He is credited with developing innovative evaluation tools to enhance...
more >
|
|
|
|
Celestia (Tia) S. Higano, M.D.
Professor, Department of Medicine, Division of Medical Oncology, University of Washington School of Medicine
Dr. Tia Higano is a prostate cancer specialist and professor of medicine at the University of Washington School of Medicine. She is also director of the Genitourinary Oncology Clinical Research Group at the University of Washington and a member of Fred Hutchinson Cancer Research Center. Dr. Higano received her medical degree from the University of Massachusetts and went on to...
more >
|
|
|
|
Richard Swanson,
Prostate Cancer Survivor
Dick Swanson, of Bellevue, WA, a semi-retired dentist and former President of the Washington State Dental Association, has been living with advanced prostate cancer for more than 20 years. He is a devoted patient advocate and leader on the internet for men with prostate cancer nationwide.
more >
|
|
|
|
